Caricamento...
Recent advances in theranostics and challenges for the future
Theranostic nuclear oncology is on the cusp of adoption into routine clinical management of neuroendocrine tumours (NETs) following publication of the Phase 3 randomised controlled trial, NETTER-1. For the first time, level 1b evidence of efficacy and safety of 68-gallium/177-lutetium-DOTA-octreotat...
Salvato in:
| Pubblicato in: | Br J Radiol |
|---|---|
| Autore principale: | |
| Natura: | Artigo |
| Lingua: | Inglês |
| Pubblicazione: |
The British Institute of Radiology.
2018
|
| Soggetti: | |
| Accesso online: | https://ncbi.nlm.nih.gov/pmc/articles/PMC6475948/ https://ncbi.nlm.nih.gov/pubmed/29565650 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1259/bjr.20170893 |
| Tags: |
Aggiungi Tag
Nessun Tag, puoi essere il primo ad aggiungerne! !
|